Apostle Inc

Executive Summary

Apostle Inc. is a privately held US biotechnology company focused on liquid biopsy and molecular diagnostics, with a core emphasis on the isolation and analysis of cell-free DNA and RNA. Founded in 2017 and headquartered in San Jose, California, the company offers a comprehensive portfolio of kits, reagents, instruments, and laboratory services targeting applications in non-invasive prenatal testing (NIPT), oncology, virology, and other clinical research areas. Apostle's technology platform is designed to enable high-sensitivity detection of circulating nucleic acids, positioning it to serve the growing demand for minimally invasive diagnostic solutions. The company is currently in Phase 3 development, indicating late-stage clinical validation and nearing potential commercialization. While financial details remain undisclosed due to its private status, Apostle's strategic focus on liquid biopsy—a rapidly expanding market—positions it as a potential player in precision diagnostics. Key challenges include regulatory hurdles, competition from established diagnostics firms, and the need for commercial partnerships to scale distribution. However, the company's differentiated approach to cfDNA/cfRNA isolation and its broad application pipeline suggest meaningful upside if it can secure regulatory clearances and strategic alliances.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for flagship liquid biopsy assay70% success
• Q3 2026Strategic partnership with major pharmaceutical company for oncology liquid biopsy50% success
• Q4 2026Series C financing round to support commercial launch80% success